ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 927,62
0,44%
Dow Jones
44 424,25
-0,32%
DAX
21 394,93
-0,11%
Brent Oil
77,165
-0,03%
Bitcoin
101 524,94
-1,11%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Chimerix Inc (CMRX) Cours

Chimerix Inc

Chimerix Inc (CMRX)

NASDAQ
3,96
0,13
(3,39%)
Fermé 27 Janvier 10:00PM
Retardé de 15 minutes
3,99
0,03
(0,76%)
Après les heures de négociation: 1:48AM
Retardé de 15 minutes

Donnez du pouvoir à votre portefeuille : discussions en temps réel et idées de trading exploitables.

Premium

Statistiques et détails clés

Dernier
3,99
Prix Achat
3,95
Prix Vente
4,00
Volume échangé
755 371
3,81 Fourchette du Jour 3,99
0,75 Plage de 52 semaines 4,07
Cap du marché
358,845M
Clôture Veille
3,83
Ouverture
3,83
Dernière Transaction
25
@
3.999
Dernière heure de transaction
Volume financier
US$ 2 939 799
VWAP
3,8919
Volume moyen (3 m)
4 828 394
Actions en circulation
89 936 053
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-4,34
Bénéfice par action (BPA)
-0,91
Chiffre d'affairess
324k
Bénéfice net
-82,1M

À propos de Chimerix Inc

Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through lice... Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through license agreements and a federal contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for research and advanced development of drugs to treat various human diseases. The company operates only in one business segment namely pharmaceuticals. Show more

Secteur
Pharmaceutical Preparations
Industrie
Pharmaceutical Preparations
Site Web
www.chimerix.com
Siège social
Wilmington, Delaware, USA
Fondé
-
Chimerix Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker CMRX. Le dernier cours de clôture d'Chimerix était de US$3,83. Au cours de la dernière année, les actions de Chimerix ont été négociées dans une fourchette de prix de US$ 0,75 à US$ 4,07.

Chimerix compte actuellement 89 936 053 actions en circulation. La capitalisation boursière d'Chimerix est de US$344,46 million. Chimerix a un ratio cours/bénéfice (ratio PE) de -4.34.

CMRX Dernières nouvelles

Plus de nouvelles

Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DURHAM, N.C., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on January 17, 2025, the Compensation Committee of Chimerix’s Board of Directors granted inducement...

24 Janvier 2025
GlobeNewswire Inc.

Chimerix to Speak Today at The White House Cancer Moonshot Forum

DURHAM, N.C., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...

13 Janvier 2025
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

10 Janvier 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

10 Janvier 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

10 Janvier 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

10 Janvier 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

10 Janvier 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

10 Janvier 2025
Edgar (US Regulatory)

Form 8-K - Current report

30 Décembre 2024
Edgar (US Regulatory)

Chimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma

DURHAM, N.C., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of...

30 Décembre 2024
GlobeNewswire Inc.
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.4111.45251396653.584.073.430115222253.76126218CS
40.6920.90909090913.34.073.1216302033.51728653CS
123.0155309.440738840.97454.070.810148283942.67573781CS
263.09343.3333333330.94.070.7523414082.5051876CS
523.055326.7379679140.9354.070.7513427572.32380767CS
156-1.43-26.38376383765.426.430.7515566062.24399331CS
2602.01101.5151515151.9811.56960.7512386173.11921731CS

CMRX - Frequently Asked Questions (FAQ)

What is the current Chimerix share price?
The current share price of Chimerix is US$ 3,99
How many Chimerix shares are in issue?
Chimerix has 89 936 053 shares in issue
What is the market cap of Chimerix?
The market capitalisation of Chimerix is USD 344,46M
What is the 1 year trading range for Chimerix share price?
Chimerix has traded in the range of US$ 0,75 to US$ 4,07 during the past year
What is the PE ratio of Chimerix?
The price to earnings ratio of Chimerix is -4,34
What is the cash to sales ratio of Chimerix?
The cash to sales ratio of Chimerix is 1,1k
What is the reporting currency for Chimerix?
Chimerix reports financial results in USD
What is the latest annual turnover for Chimerix?
The latest annual turnover of Chimerix is USD 324k
What is the latest annual profit for Chimerix?
The latest annual profit of Chimerix is USD -82,1M
What is the registered address of Chimerix?
The registered address for Chimerix is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Chimerix website address?
The website address for Chimerix is www.chimerix.com
Which industry sector does Chimerix operate in?
Chimerix operates in the PHARMACEUTICAL PREPARATIONS sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
NVNINVNI Group Ltd
US$ 4,38
(193,96%)
366,98M
EVAXEvaxion Biotech AS
US$ 5,99
(64,56%)
55,41M
ELABPMGC Holdings Inc
US$ 3,0901
(56,07%)
76,48M
PCLAPicoCELA Inc
US$ 4,60
(49,35%)
3,75M
GOEVCanoo Inc
US$ 0,475
(43,94%)
282,22M
GODNUGolden Star Acquisition Corporation
US$ 3,11
(-75,82%)
17,51k
GODNGolden Star Acquisition Corporation
US$ 2,93
(-65,67%)
902,76k
NXTTNext Technology Holding Inc
US$ 1,37
(-54,93%)
2,56M
SGLYSingularity Future Technology Ltd
US$ 1,625
(-38,45%)
917,77k
WHLRLWheeler Real Estate Investment Trust Inc
US$ 90,11
(-38,07%)
8
ACONAclarion Inc
US$ 0,0557
(28,94%)
811,91M
NVNINVNI Group Ltd
US$ 4,38
(193,96%)
366,98M
RIMEAlgorhythm Holdings Inc
US$ 0,0357
(4,69%)
284,97M
GOEVCanoo Inc
US$ 0,475
(43,94%)
282,22M
NVDANVIDIA Corporation
US$ 142,62
(-3,12%)
232,88M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
CMRX
Chimerix
EU
FRSG00014DG2
SG Issuer Sg Issuer Mc A...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2025 ADVFN PLC - Tous droits réservés